165 related articles for article (PubMed ID: 15291652)
1. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review.
Sevy S; Visweswaraiah H; Mentschel C; Leucht S; Schooler NR
J Clin Psychiatry; 2004 Jun; 65(6):756-65. PubMed ID: 15291652
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
4. The NIMH-CATIE Schizophrenia Study: what did we learn?
Lieberman JA; Stroup TS
Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492
[No Abstract] [Full Text] [Related]
5. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
6. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
McCombs JS; Luo M; Johnstone BM; Shi L
Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
[TBL] [Abstract][Full Text] [Related]
7. The costs of drugs for schizophrenia.
Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
9. New antipsychotic agents: emerging clinical profiles.
Buckley PF
J Clin Psychiatry; 1999; 60 Suppl 1():12-7; discussion 28-30. PubMed ID: 10037165
[TBL] [Abstract][Full Text] [Related]
10. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Glazer WM; Johnstone BM
J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
[TBL] [Abstract][Full Text] [Related]
12. The cost of schizophrenia.
Wasylenki DA
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S65-9. PubMed ID: 7874667
[TBL] [Abstract][Full Text] [Related]
13. Use of conventional antipsychotics and the cost of treating schizophrenia.
Lyu RR; McCombs JS; Johnstone BM; Muse DN
Health Care Financ Rev; 2001; 23(2):83-99. PubMed ID: 12500340
[TBL] [Abstract][Full Text] [Related]
14. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
15. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
[TBL] [Abstract][Full Text] [Related]
16. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Rosenheck RA
Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
[No Abstract] [Full Text] [Related]
17. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.
Tunis SL; Johnstone BM; Kinon BJ; Barber BL; Browne RA
Value Health; 2000; 3(3):232-42. PubMed ID: 16464187
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
Essock SM; Frisman LK; Covell NH; Hargreaves WA
Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
[TBL] [Abstract][Full Text] [Related]
19. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
Rosenheck RA; Lieberman JA
J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
